KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells

Cancer Research

Volumn 73, Issue 14, 2013, Pages 4406-4417

  Xu, Yong ^a   Fang, Fang ^b   Miriyala, Sumitra ^a   Crooks, Peter A ^c   Oberley, Terry D ^d   Chaiswing, Luksana ^d   Noel, Teresa ^a   Holley, Aaron K ^a   Zhao, Yanming ^a   Kiningham, Kelley K ^e   Clair, Daret K St ^a   Clair, William H St ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e BELMONT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRININ; COPPER ZINC SUPEROXIDE DISMUTASE; DIMETHYLAMINOPARTHENOLIDE; GLUTATHIONE PEROXIDASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL ENZYME; PARTHENOLIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOGLYCERATE MUTASE 5; PROTEIN BCL XL; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER INJURY; CANCER CELL; CANCER RADIOTHERAPY; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; EPITHELIUM CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN TARGETING; RADIATION INJURY; RADIOSENSITIVITY; RADIOSENSITIZATION; TISSUE INJURY; TUMOR XENOGRAFT;

ANIMALS; ANTIOXIDANTS; BCL-X PROTEIN; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; EPITHELIAL CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, NUDE; MITOCHONDRIAL PROTEINS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES; SESQUITERPENES; THIOREDOXINS; UBIQUITIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880885989     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4297     Document Type: Article

References (48)

1. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997;275:1649-52.
2. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006;312:1882-83.
3. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97-110.
4. Tew KD, Townsend DM. Redox platforms in cancer drug discovery and development. Curr Opin Chem Biol 2011;15:156-61.
5. D'Autreaux B, Toledano MB. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007;8:813-24.
6. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Rojanasakul Y, Wang XR, et al. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007;67: 10823-30.
7. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
8. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
9. Cabello CM, Bair WB III, Wondrak GT. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 2007;8:1022-37.
10. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008;10:1343-74.
11. Wang J, Yi J. Cancer cell killing via ROS to increase or decrease, that is the question. Cancer Biol Ther 2008;7:1875-84.
12. Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy. Cancer Lett 2012;327: 111-22.
13. Oberley L, Oberley TD. Role of antioxidant enzymes in cell immortalization and transformation. Mol Cell Biochem 1988;84:147-53.
14. Zhao Y, Chaiswing L, Oberley TD, Batinic-Haberle I, St Clair W, Epstein CJ, et al. A mechanism-based antioxidant approach for the reduction of skin carcinogenesis. Cancer Res 2005;65:1401-5.
15. Dhar SK, Tangpong J, Chaiswing L, Oberley TD, Clair DK. Manganese superoxide dismutase is a p53-regulated gene that switches cancers between early and advanced stages. Cancer Res 2011;71: 6684-95.
16. Josson S, Xu Y, Fang F, Dhar SK, Clair DK, Clair WH. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006;25: 1554-59.
17. Fan M, Ahmed KM, Coleman MC, Spitz DR, Li JJ. Nuclear factorkappaB and manganese superoxide dismutase mediate adaptive radioresistance in low-dose irradiated mouse skin epithelial cells. Cancer Res 2007;67:3220-28.
18. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009;15:3423-32.
19. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, et al. Chemical genomic screening reveals synergismbetween parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010;116:5983-90.
20. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011;475:231-34.
21. Hwang DR, Wu YS, Chang CW, Chang CW, Lien TW, Chen WC, et al. Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorg Med Chem 2006;14:83-91.
22. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide- dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol 2008;46:129-35.
23. Gill KK, Kaddoumi A, Nazzal S. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosensitization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci 2012;46:64-71.
24. Sun Y, Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, et al. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 2007;9:2477-86.
25. Sun Y, Clair DK, Xu Y, Crooks PA, Clair WH. A NADPH oxidasedependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 2010;70:2880-90.
26. Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007;13:59-67.
27. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, et al. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 2003;423:769-73.
28. Rasmussen HH, Hamilton EJ, Liu CC, Figtree GA. Reversible oxidative modification: implications for cardiovascular physiology and pathophysiology. Trends Cardiovasc Med 2010;20:85-90.
29. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 2004;101:2040-45.
30. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011;20:524-37.
31. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: discovery of the NFkappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett 2009;19: 4346-9.
32. Xu Y, Fang F, Clair DK, Josson S, Sompol P, Spasojevic I, et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha, 25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 2007;6:2048-56.
33. Xu Y, Josson S, Fang F, Clair DK, Wan XS, Sun Y, et al. RelB enhances prostate cancer growth: implications for the role of the NFkB alternative pathway in tumorigenicity. Cancer Res 2009;69: 3267-71.
34. 2, oxidative stress, and genomic instability. Cancer Res 2006;66:7615-20.
35. Bayer EA, Safars M, Wilchek M. Selective labeling of sulfhydryls and disulfides on blot transfers using avidin-biotin technology: studies on purified proteins and erythrocyte membranes. Anal Biochem 1987;161:262-71.
36. Keller JN, Kindy MS, Holtsberg FW, Clair DK, Yen HC, Germeyer A, et al., Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 1998;18:687-97.
37. Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC, et al. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2010;107: 7479-84.
38. Lo SC, Hannink M. PGAM5, a Bcl-xL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex. J Biol Chem 2006;281:37893-903.
39. Niture SK, Jaiswal AK. Inhibitor of Nrf2 (INrf2 or Keap1) protein degrades Bcl-xL via phosphoglycerate mutase 5 and controls cellular apoptosis. J Biol Chem 2011;286:44542-56.
40. Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH, et al. Parthenolide, an NF-kB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011;8:39-47.
41. Zuch D, Giang AH, Shapovalov Y, Schwarz E, Rosier R, O'Keefe R, et al. Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem 2012;113:1282-91.
42. Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011;71:1385-96.
43. Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010;244: 21-26.
44. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 2010;30: 3275-85.
45. Rusten TE, Stenmark H. p62, an autophagy hero or culprit? Nat Cell Biol 2010;12:207-9.
46. Van der Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997;91:627-37.
47. Weinberg F, Chandel NS. Mitochondrial metabolism and cancer. Ann NY Acad Sci 2009;1177:66-73.
48. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal 2012;16:1264-84.